Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels. Goldman Sachs has just initiated coverage on ResMed and named it ...

Dave Whelan's requests for a sleep apnoea test were repeatedly ignored until he suffered a near fatal crash on the M11 which ...

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE ... strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

Shares of ResMed Inc. RMD rose 1.12% to $239.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and the ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...